Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
CC transcript
Appointed director
|
|
Ocera Therapeutics, Inc. (OCRX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 12/07/2017 |
GN
| SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Files Class Action Suit Against Ocera Therapeutics, Inc. |
| 11/02/2017 |
GN
| Mallinckrodt to Acquire Ocera Therapeutics and OCR-002, its Proprietary Therapy in Development for Treatment of Hepatic Encephalopathy |
| 10/20/2017 |
GN
| Ocera Presents Three Posters and an Oral Presentation on OCR-002 at the AASLD Liver Meeting® |
| 08/01/2017 |
GN
| Ocera Therapeutics Reports Second Quarter 2017 Financial Results |
| 06/01/2017 |
GN
| Ocera Initiates Phase 2a Study with Oral OCR-002 in Patients with Cirrhosis |
| 05/26/2017 |
GN
| Ocera Therapeutics to Host KOL Conference Call on Hepatic Encephalopathy and Other Complications of Liver Disease on Friday, June 2 |
| 05/03/2017 |
GN
| Ocera Therapeutics to Report First Quarter 2017 Financial Results and Provide Clinical Update on May 9, 2017 |
| 04/12/2017 |
GN
| Ocera Therapeutics Announces Presentation of Data Showing OCR-002 Prevented Progression of Fibrosis in Preclinical Model of Non-alcoholic Fatty Liver Disease (NAFLD) |
| 03/27/2017 |
GN
| Ocera to Present at the 16th Annual Needham Healthcare Conference |
| 03/10/2017 |
GN
| Ocera Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update |
| 03/08/2017 |
GN
| Ocera to Announce Additional Encouraging Results from its Phase 2b STOP-HE Study of IV OCR-002 in Patients with Hepatic Encephalopathy |
| 01/30/2017 |
GN
| Ocera Announces Top-line Results for Phase 2b Study in Hepatic Encephalopathy |
| 10/03/2012 |
GN
| Tranzyme Pharma to Present at BIO Investor Forum on October 10, 2012 |
| 09/18/2012 |
GN
| Tranzyme Pharma Announces Exercise of Underwriters' Over-Allotment Option and Closing of $11.5 Million Registered Direct Offering of Common Stock |
| 08/23/2012 |
GN
| Tranzyme Pharma to Present at the Stifel Nicolaus Healthcare Conference on September 5, 2012 |
| 08/09/2012 |
GN
| Tranzyme Pharma Announces Second Quarter 2012 Financial Results |
| 08/01/2012 |
GN
| Tranzyme Pharma to Present at the Canaccord Genuity 32nd Annual Growth Conference on August 14, 2012 |
| 06/26/2012 |
GN
| Tranzyme Pharma to Present at the Seventh Annual JMP Securities Healthcare Conference in New York |
| 06/06/2012 |
GN
| Tranzyme Pharma to Present TZP-102 Data at ADA June 8-12, 2012 in Philadelphia, PA |
| 05/30/2012 |
GN
| Tranzyme Pharma to Present at the Jefferies 2012 Global Healthcare Conference on June 4, 2012 |
| 05/25/2012 |
GN
| Tranzyme Pharma and Norgine Announce Top-Line Data From ULISES 008, the Second of Two Phase 3 Pivotal Trials Evaluating Ulimorelin |
|
|